Conditions Most Often Studied in Medical Cannabis Research

Medical cannabis is discussed as though the evidence were uniform across conditions. It is not. For a small number of indications the research is solid. For many more it is preliminary, mixed, or based on laboratory work that has not translated to people.

This is a condition-by-condition summary of where the research actually stands, written to be useful rather than promotional.

How to Read What Follows

Evidence quality varies enormously, and it is worth being explicit about the tiers:

• Strong — supported by randomised controlled trials, often with regulatory approval of a specific formulation.
• Moderate — multiple trials with consistent findings, usually modest effect sizes.
• Limited — small trials, mixed results, or observational data only.
• Preclinical — cell or animal studies. Most preclinical findings do not translate to human benefit.

The methodological reasons cannabis research is difficult — blinding problems, non-standardised interventions, regulatory barriers — are covered in the science behind medical cannabis research. They apply to everything below.

Chemotherapy-Induced Nausea and Vomiting

Evidence: strong.

Among the best-established indications. Synthetic cannabinoid medications have held regulatory approval for this for decades, supported by trials showing benefit compared with older antiemetics.

Newer antiemetic drugs have changed the clinical picture, and cannabinoids are generally considered where conventional options have not worked adequately. Nonetheless this remains the clearest case in the field.

Severe Epilepsy Syndromes

Evidence: strong, for specific syndromes and a specific formulation.

A purified pharmaceutical CBD formulation holds regulatory approval for Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, supported by randomised controlled trials showing reduced seizure frequency.

Two qualifications matter. This applies to a specific purified formulation at specific doses under medical supervision, not to CBD products generally. And clinically important interactions exist — with clobazam in particular — which is why this requires prescriber oversight. See cannabis and drug interactions.

The case that drove attention to this area is covered in Charlotte Figi and the turning point for CBD.

Multiple Sclerosis Spasticity

Evidence: strong to moderate.

A standardised THC:CBD oromucosal spray is approved in several countries for spasticity in multiple sclerosis where other treatments have not worked. Trial evidence supports improvement in patient-reported spasticity, with more modest effects on objective measures.

Chronic Pain

Evidence: moderate, with modest effect sizes.

The most studied indication and the most common reason people use medical cannabis.

Systematic reviews generally find that cannabinoids produce a modest reduction in chronic pain compared with placebo, with the clearest signal in neuropathic pain. The effect is real and smaller than the marketing suggests — reviews typically describe a small number of patients achieving meaningful pain reduction who would not have on placebo.

Evidence is weaker for other pain types, and long-term effectiveness data is limited. Side effects — dizziness, sedation, cognitive effects — cause a meaningful proportion of trial participants to discontinue.

The Opioid Question

Evidence: limited and contested.

The proposition that cannabis reduces opioid use has attracted considerable attention, and the evidence is more ambiguous than either side presents.

Some ecological studies found lower opioid prescribing or overdose rates in states with medical cannabis laws. Later analyses over longer periods produced different results, and this type of study cannot establish causation at the individual level.

Observational studies of patients report reduced opioid use after starting cannabis. These rely on self-report and lack control groups.

Controlled trials directly testing cannabis as an opioid-sparing intervention are few, and results are mixed.

A fair summary: plausible, of real public health interest, and not established. It should not be presented to patients as a demonstrated route off opioids, and opioid tapering should be managed clinically regardless.

Addiction and Substance Use

Evidence: limited.

Research has examined cannabinoids — CBD particularly — in the context of substance use disorders, with some small studies suggesting reduced cue-induced craving in opioid and tobacco use.

These are early findings. Cannabis itself also carries dependence potential, with cannabis use disorder affecting a meaningful minority of regular users, which complicates the framing.

Gastrointestinal Conditions

Evidence: limited.

Cannabinoid receptors are present throughout the gastrointestinal tract, and the endocannabinoid system participates in gut motility and inflammatory signalling — a plausible mechanism.

Small trials in Crohn’s disease have reported symptomatic improvement and, notably, generally without corresponding improvement in objective markers of inflammation. That distinction matters: feeling better and having less disease activity are different outcomes, and cannabis appearing to deliver the first without the second is a real finding rather than a technicality.

Evidence in ulcerative colitis and irritable bowel syndrome is thinner.

Worth noting the opposite direction too: cannabinoid hyperemesis syndrome — cyclical severe vomiting in some heavy long-term users — is well documented and frequently misdiagnosed for years.

Parkinson’s Disease

Evidence: limited to preclinical.

Interest here comes from the endocannabinoid system’s role in motor control. Some small studies and survey data report improvements in tremor, sleep and anxiety among people with Parkinson’s using cannabis.

Controlled trial evidence is sparse, and results have not consistently shown improvement in motor symptoms. Effects on non-motor symptoms such as sleep and anxiety may be more promising than effects on the movement disorder itself. Interactions with Parkinson’s medications are an additional consideration.

Glaucoma

Evidence: understood, and largely negative in practice.

This one deserves precision because it is widely misunderstood.

THC does reduce intraocular pressure — that is established and has been known since the 1970s. The problem is duration: the effect lasts only a few hours. Managing glaucoma requires continuous pressure control, which would mean dosing every three to four hours around the clock, indefinitely, with the associated intoxication and tolerance.

Professional ophthalmology bodies have generally concluded that cannabis is not a practical glaucoma treatment and that established medications are more effective and far more manageable. Relying on cannabis instead of prescribed treatment risks irreversible vision loss.

Cancer

Evidence: strong for some symptom management; preclinical only for anti-tumour claims.

This distinction is the most important on the page.

For symptoms and treatment side effects — nausea and vomiting from chemotherapy, appetite loss, pain — there is reasonable supporting evidence, as above.

For treating cancer itself — the evidence is preclinical. Laboratory studies have shown cannabinoids affecting cancer cells in culture and in animal models. This has not translated into human trials showing that cannabis treats cancer.

Preclinical results are how research begins, and the large majority of compounds that kill cancer cells in a dish never become treatments. Presenting this work as evidence that cannabis treats cancer is not supported, and patients declining or delaying conventional treatment on that basis is a documented and serious harm.

Reproductive and Menstrual Conditions

Evidence: very limited.

Cannabis has a long history of use for menstrual pain, and cannabinoid receptors are present in reproductive tissue. Survey data indicates substantial use for menstrual pain, endometriosis and menopausal symptoms.

Controlled trial evidence is close to absent. Historical use and biological plausibility are reasons to study something, not substitutes for having studied it.

Use during pregnancy and breastfeeding is a separate matter, where the evidence that does exist raises concerns and professional guidance advises against it.

What This Adds Up To

A small number of indications with genuine trial support. A larger number where the research is early, mixed or absent. And a persistent gap between what is marketed and what has been shown.

None of that means cannabis does not help people. It means that for most conditions, we do not have the evidence to say how much, for whom, or at what dose — and that honest uncertainty is more useful than confident claims in either direction.

If you are considering medical cannabis, the productive step is a conversation with a clinician who knows your history and your medications. See working with a qualified cannabis clinician, understanding medical cannabis, and cannabis and mental health.